As previously mentioned, obesity significantly impacts the effectiveness of pharmacological therapy, mainly in PsA, particularly TNF-α inhibitors, whereas drugs targeting the IL-23/IL-17 axis appear to be less affected by the presence of obesity [17]. Here, IL17A is linked to obesity due to melanocortin 4 receptor deficiency.